IRIS
DE TURSI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.581
EU - Europa 2.601
AS - Asia 1.227
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 9
SA - Sud America 6
OC - Oceania 2
Totale 7.437
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.570
IE - Irlanda 672
IT - Italia 505
SG - Singapore 457
SE - Svezia 420
CN - Cina 414
UA - Ucraina 265
FR - Francia 207
TR - Turchia 174
GB - Regno Unito 156
DE - Germania 133
IN - India 113
RU - Federazione Russa 84
FI - Finlandia 48
VN - Vietnam 48
BE - Belgio 42
CZ - Repubblica Ceca 18
EU - Europa 11
AT - Austria 10
PL - Polonia 10
CA - Canada 9
HK - Hong Kong 6
RO - Romania 6
EG - Egitto 5
JP - Giappone 5
ES - Italia 4
LT - Lituania 4
PT - Portogallo 4
GR - Grecia 3
NL - Olanda 3
CL - Cile 2
CO - Colombia 2
ID - Indonesia 2
MA - Marocco 2
PK - Pakistan 2
TW - Taiwan 2
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
DZ - Algeria 1
IR - Iran 1
KR - Corea 1
LV - Lettonia 1
MM - Myanmar 1
MT - Malta 1
MX - Messico 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 7.437
Salva come PNG Salva come JPEG
Città #
Chandler 877
Dublin 648
Jacksonville 452
Singapore 390
Princeton 264
Ashburn 181
Nanjing 127
Chieti 116
Izmir 114
Southend 108
Dearborn 106
Wilmington 106
Altamura 100
Beijing 92
Santa Clara 92
Ann Arbor 89
Boardman 57
Los Angeles 56
Cambridge 54
New York 48
Dong Ket 47
Brussels 41
Washington 39
Menlo Park 36
Nanchang 30
Shenyang 24
Norwalk 21
Falls Church 19
Hebei 19
Kunming 19
Woodbridge 19
Pescara 18
Rome 18
Houston 15
Munich 15
Seattle 15
Tianjin 15
Jiaxing 13
Hangzhou 12
Brno 11
Edinburgh 10
Milan 10
Vienna 10
Helsinki 9
Pune 9
Redwood City 9
Grevenbroich 8
Kraków 8
Changchun 7
Hefei 7
Changsha 6
Hong Kong 6
London 6
Mcallen 6
Cairo 5
Giaveno 5
Guangzhou 5
Lanciano 5
Pisa 5
Simi Valley 5
Tappahannock 5
Tokyo 5
L’Aquila 4
Madrid 4
Rouen 4
Shanghai 4
Altino 3
Ameno 3
Amsterdam 3
Aprilia 3
Bangalore 3
Garden City 3
Jinan 3
Lanzhou 3
Montreal 3
Moscow 3
Olomouc 3
Ottawa 3
Paris 3
Perego 3
Prague 3
Redmond 3
Sulmona 3
Tucson 3
Andover 2
Antrodoco 2
Bari 2
Bogotá 2
Bordeaux 2
Boston 2
Chengdu 2
Chicago 2
Collecorvino 2
Fairfield 2
Frankfurt am Main 2
Isernia 2
Islamabad 2
Jakarta 2
Jinhua 2
Lappeenranta 2
Totale 4.776
Salva come PNG Salva come JPEG
Nome #
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 115
PERITONECTOMIA ED HIPEC NEL TRATTAMENTO DELLA CARCINOSI PERITONEALE: RISULTATI PRELIMINARI DOPO UN ANNO DI ESPERIENZA 111
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 111
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 109
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 100
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 98
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 97
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 92
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 90
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 90
Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group 90
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 88
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 88
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 86
Principali effetti collaterali delle terapie mediche 86
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 86
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 85
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 84
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 83
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 83
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 82
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 81
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 80
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 80
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 80
Speed rate (SR) as a new dynamic index of melanoma behavior 79
New Targets for Therapy in Pancreatic Cancer 78
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 78
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 77
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 76
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 76
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 76
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 74
Rivaroxaban for cancer-associated cardiac thrombosis 74
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 73
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 72
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 72
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 72
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 72
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 71
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 70
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 70
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 69
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 69
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 68
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 68
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 67
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 67
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 66
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 66
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 66
null 65
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 65
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 65
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 65
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 64
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 64
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 63
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 63
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 63
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 62
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 62
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 61
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 61
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 61
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 61
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 60
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 60
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 59
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 58
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 58
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 58
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 57
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 57
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 56
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 56
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 55
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. 54
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 54
PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 54
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 53
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 53
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 53
Nivolumab and diabetes mellitus: safe administration in a patient with pancreatic metastases from melanoma 52
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 52
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 52
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 52
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 51
Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP) 51
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 51
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 50
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 50
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. 49
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 49
Poor risk metastatic renal cell carcinoma (mRCC) patients are not a homogeneous group: a new stratificating model in the era of targeted therapy. 48
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 48
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 48
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review 47
High blood concentration of circulating cancer stem cell-derived extracellular vesicles is associated with poor survival in advanced colorectal cancer patients 47
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 46
Totale 6.884
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.380
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.380
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020813 0 0 0 24 93 92 143 71 71 134 169 16
2020/2021818 123 28 154 21 51 169 33 24 58 51 30 76
2021/2022805 19 28 14 193 75 26 20 43 51 20 69 247
2022/20232.331 206 323 188 257 166 412 116 216 273 23 103 48
2023/20241.044 63 32 79 34 67 395 178 43 25 35 10 83
2024/2025896 134 454 304 4 0 0 0 0 0 0 0 0
Totale 8.156